A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29

Turner, John T.; Jones, Susan B.; Bylund, David B.

doi:10.1016/0196-9781(86)90105-1

Cited by 83 publications

(35 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the cell lines responded to a similar range of secretory and antisecretory agents. Indeed, the VIP EC50 values for the HT-29 wt (11.7 nM) and Yl clones are remarkably similar and correlate well with those for stimulation of anion secretion in the rat jejunum (12 nM;Cox & Cuthbert, 1989) and for stimulation of adenylyl cyclase activity in HT-29 wt (2.9 nM; Turner et al, 1986) (Cox & Tough, 1995;Tough & Cox, 1996). PYY EC50 values for the inhibition of VIP-stimulated SCC varied between the Yl clones, possibly due to differences in the level of receptor expression (e.g.…”

Section: Pro34mentioning

confidence: 54%

“…Y1-16 (Turner et al, 1986), indicates that PYY is likely to exert its effect through an inhibition of adenylyl cyclase; there was no evidence of an increase in cytosolic calcium after activation of the receptor, which in HT-29 cells produces a transient increase in SCC. Apical additions of PYY were associated with much smaller responses in Y 1-7 cells, suggesting that, at least in this clone, the transfected receptor is targeted to the basolateral membrane.…”

Section: Pro34mentioning

confidence: 99%

See 1 more Smart Citation

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor

Holliday

Cox

1996

British J Pharmacology

View full text Add to dashboard Cite

1 The human adenocarcinoma cell line, HT-29, has been stably transfected with the cDNA sequence for the rat neuropeptide Y (NPY) Y1 receptor, and three Y1 clones (Y1-4, Y1-7 and Y1 -16) have been isolated which express high levels of specific ['251 6 HT-29 clones stably expressing the Y1 receptor therefore show responses to PYY and its analogues that are characteristic of that subtype, and the Y1-7 clone in particular will be useful in the assessment of novel Y1-specific drugs. This approach will also allow the functional study of NPY Y1 receptors with selected mutations.

show abstract

Section: Pro34mentioning

confidence: 54%

Section: Pro34mentioning

confidence: 99%

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor

Holliday

Cox

1996

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…The peptides were also chosen because they have been reported to have growth stimulating activity on cells which would be consistent with them having angiogenic activity. Thus, one reason for choosing VIP for this study is that it is not only a potent vasodilator (Said & Mutt, 1970;Hattori et al, 1992) but regulates various immune cells (O'Dorisio et al, 1985) and stimulates the proliferation of many cell types in vitro (Bepler et al, 1988;Zurier et al, 1988;Haegerstrand et al, 1989;Pincus et al, 1990;Takahashi et al, 1993 leukin-lIa was inhibited by co-administration of a VIP receptor antagonist, VIP (10-28) (Turner et al, 1986). These data suggest that the angiogenic effect of VIP in the rat is mediated by a specific VIP receptor but determination of whether or not VIP is an endothelial mitogen awaits further investigation.…”

Section: Discussionmentioning

confidence: 99%

“…Histological studies of sponge sections showed that both cellular infiltration and neovascularisation in the sponges treated with either VIP or co-administration of VIP and interleukin-la were greatly increased as compared to controls (Figure 2). The neovascular response induced by co-administration of VIP and interleukin-la was inhibited by simultaneous administration of 100 pmol VIP (10-28), a specific VIP receptor antagonist (Turner et al, 1986; Figure 3). The effect of VIP (10-28) on VIP-induced angiogenesis was confirmed histologically (Figure 2).…”

Section: Effect Of Vip On Sponge-induced Angiogenesismentioning

confidence: 99%

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Hiley

Fan

1996

British J Pharmacology

View full text Add to dashboard Cite

The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin‐1, endothelin‐3 and angiotensin II, were investigated in a rat sponge model. Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies. Daily doses of the vasodilator peptide, VIP (1000 pmol), caused intense neovascularization, but a lower dose (10 pmol) produced no apparent effect. However, the lower dose of VIP, when given with a subthreshold dose of interleukin‐1α (0.3 pmol), produced an angiogenic response similar to that seen with the higher dose of VIP. The neovascular response induced by co‐administration of VIP and interleukin‐1α was inhibited by simultaneous administration of 100 pmol VIP (10–28), a specific VIP receptor antagonist. In contrast, daily doses of 10, 100 or 1000 pmol endothelin‐3 (a mixed vasoconstrictor and vasodilator with more marked vasodilator activity) or of 100 or 1000 pmol endothelin‐1 (also with mixed activity but with much more pronounced vasoconstrictor response) produced no apparent effect on sponge‐induced angiogenesis. The vasoconstrictor peptide, angiotensin II, in daily doses of 1000 pmol, caused an intense neovascularization like VIP but lower doses of angiotensin II (10 or 100 pmol) produced no apparent effect. The lowest dose of angiotensin II (10 pmol) when administered with the subthreshold dose of interleukin‐1α (0.3 pmol) had no effect on the basal neovascular response in the sponges. The angiotensin II‐induced neovascular response was inhibited by co‐administration of 100 nmol of the specific AT1 receptor antagonist, losartan, but not by the AT2 receptor antagonist, PD 123319. These data show that VIP and angiotensin II possess angiogenic activity. However, endothelin‐1 and endothelin‐3 had no activity at the doses used. Thus the angiogenic response is not related to local vasoconstriction or vasodilatation in the sponges. The blockade of VIP‐ and angiotensin II‐induced angiogenesis at the receptor level suggests that receptor modulation could provide a strategy for the management of angiogenic diseases.

show abstract

“…5). We used a partial sequence fragment of VIP, VIP10 -28, which functions as a VIPR antagonist (30,31). VIP10 -28 blocks NANC transmission Ͼ50% in WT preparations, demonstrating the critical role of endogenous VIP released from neurons in mediating NANC relaxation (Fig.…”

Section: Ho2 ؊/؊ Mice Have Reduced Electrical-field Stimulation (Efs)mentioning

confidence: 99%

Carbon monoxide mediates vasoactive intestinal polypeptide-associated nonadrenergic/noncholinergic neurotransmission

Watkins

Boehning

Kaplin

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Carbon monoxide (CO) synthesized by heme oxygenase 2 (HO2) and nitric oxide (NO) produced by neuronal NO synthase (nNOS) mediate nonadrenergic͞noncholinergic (NANC) intestinal relaxation. In many areas of the gastrointestinal tract, NO and CO function as coneurotransmitters. In the internal anal sphincter (IAS), NANC relaxation is mediated primarily by CO. Vasoactive intestinal polypeptide (VIP) has also been shown to participate in NANC relaxation throughout the intestine, including the IAS. By using a combination of pharmacology and genetic knockout of the biosynthetic enzymes for CO and NO, we show that the physiologic effects of exogenous and endogenous VIP in the IAS are mediated by HO2-synthesized CO.

show abstract

A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29

Cited by 83 publications

References 14 publications

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Carbon monoxide mediates vasoactive intestinal polypeptide-associated nonadrenergic/noncholinergic neurotransmission

Contact Info

Product

Resources

About

A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29

Cited by 83 publications

References 14 publications

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Carbon monoxide mediates vasoactive intestinal polypeptide-associated nonadrenergic/noncholinergic neurotransmission

Contact Info

Product

Resources

About

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor

The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y₁ receptor